{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:18:03Z","timestamp":1787807883287,"version":"build-2784847793"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While dupilumab is widely used for atopic dermatitis (AD), its safety and effectiveness in patients with severe renal failure remain insufficiently studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness and renal safety of dupilumab in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This cohort study included 30 adult moderate-to-severe AD patients with Chronic Kidney Disease (CKD) stages 4\u20135. Patients were divided into a dupilumab-treated group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917) and a control group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913) receiving conventional therapy. Effectiveness was assessed using the Peak Pruritus Numerical Rating Scale and Investigator's Global Assessment. Renal safety was evaluated via eGFR and serum creatinine levels, analyzed using linear mixed-effects models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The dupilumab group showed a numerically greater PP-NRS reduction at Day 30 (4.6 vs. 2.7 points) with a trend toward sustained improvement; however, the between-group difference did not reach statistical significance in the mixed-effects model (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.109). IGA scores showed similar trends. Regarding renal safety, despite poorer baseline renal function in the dupilumab group, the degree of renal function decline was not statistically different from that in the control group. Sensitivity analysis excluding patients on dialysis did not alter this conclusion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dupilumab was associated with a numerical trend toward greater improvement in pruritus compared with conventional therapy, and was not associated with statistically detectable acceleration of renal function decline in AD patients with CKD stages 4\u20135. These preliminary findings require confirmation in larger prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1889589","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:13Z","timestamp":1787804773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and renal safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis patients with chronic kidney disease stages 4\u20135: a real-world cohort study in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Gang","family":"Hu","sequence":"first","affiliation":[{"name":"School of Medicine, Jianghan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Department of Dermatovenereology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoyao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuhan No.1 Hospital","place":["Wuhan, China"]},{"name":"Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanglin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Wuhan No.1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine, Jianghan University","place":["Wuhan, China"]},{"name":"Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Department of Dermatology, Wuhan No.1 Hospital","place":["Wuhan, China"]},{"name":"Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e13899","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American academy of allergy, asthma and immunology\/American college of allergy, asthma and immunology joint task force on practice parameters GRADE- and institute of medicine-based recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpdd.798","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects","volume":"9","author":"Li","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1517\/17460441.3.3.289","article-title":"Preclinical development of therapeutic biologics","volume":"3","author":"Baumann","year":"2008","journal-title":"Expert Opin Drug Discov"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.1002\/mco2.707","article-title":"Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China","volume":"5","author":"Peng","year":"2024","journal-title":"MedComm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1159\/000546130","article-title":"Association between systemic inflammation and worsening renal function in cardiovascular-kidney-metabolic syndrome","volume":"56","author":"Wang","year":"2025","journal-title":"Am J Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/toxins14030197","article-title":"The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: What Can We Expect?","volume":"14","author":"Swierczynska","year":"2022","journal-title":"Toxins (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"638325","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaad.2025.03.067","article-title":"Efficacy of dupilumab for chronic kidney disease-associated pruritus in patients undergoing hemodialysis: retrospective observational study","volume":"93","author":"Wang","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/life12122002","article-title":"Treatment of severe atopic dermatitis with dupilumab in three patients with renal diseases","volume":"12","author":"Foti","year":"2022","journal-title":"Life (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e27439","DOI":"10.7759\/cureus.27439","article-title":"Generalized granuloma Annulare associated with dupilumab therapy","volume":"14","author":"Phelps-Polirer","year":"2022","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1159\/000518391","article-title":"Chronic kidney disease-associated pruritus: a review","volume":"46","author":"Makar","year":"2021","journal-title":"Kidney and Blood Pressure Research"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1889589\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:13Z","timestamp":1787804773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1889589\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":15,"alternative-id":["10.3389\/fmed.2026.1889589"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1889589","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1889589"}}